Patents Assigned to VIGIL NEUROSCIENCE, INC.
  • Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
    Patent number: 11884675
    Abstract: The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 (“TREM2”). This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.
    Type: Grant
    Filed: November 30, 2022
    Date of Patent: January 30, 2024
    Assignees: AMGEN INC., VIGIL NEUROSCIENCE, INC
    Inventors: Lara C. Czabaniuk, Timothy Hopper, Jonathan B. Houze, Jane Panteleev, Gwenaella Rescourio, Vincent Santora, Haoxuan Wang, Ryan D. White, Alice R. Wong, Yongwei Wu, Maxence Bos, John Mancuso, Ivan Franzoni
  • Heterocyclic compounds as triggering receptor expressed on myeloid cells2 agonists and methods of use
    Patent number: 11718617
    Abstract: The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 (“TREM2”). This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.
    Type: Grant
    Filed: November 30, 2022
    Date of Patent: August 8, 2023
    Assignees: AMGEN INC., Vigil Neuroscience, Inc.
    Inventors: Lara C. Czabaniuk, Timothy Hopper, Jonathan B. Houze, Gwenaella Rescourio, Vincent Santora, Haoxuan Wang, Ryan D. White, Alice R. Wong, Yongwei Wu
  • Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
    Patent number: 11608344
    Abstract: The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 (“TREM2”). This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.
    Type: Grant
    Filed: May 4, 2021
    Date of Patent: March 21, 2023
    Assignees: AMGEN INC., VIGIL NEUROSCIENCE, INC.
    Inventors: Lara C. Czabaniuk, Timothy Hopper, Jonathan B. Houze, Jane Panteleev, Gwenaella Rescourio, Vincent Santora, Haoxuan Wang, Ryan D. White, Alice R. Wong, Yongwei Wu, Maxence Bos, John Mancuso, Ivan Franzoni